Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting; In the Phase 3b/4 PSORIATYK SCALP trial Sotyktu was superior to placebo across

Press/Media

Period27 Sep 2024 → 28 Sep 2024

Media coverage

16

Media coverage